Sodium Selenate as a Disease-Modifying Treatment for Mild to Moderate Alzheimer’s Disease: An Open-Label Extension Study
December 2021
in “
BMJ neurology open
”
Studysummary This study on Alzheimer's patients found that chronic sodium selenate treatment (up to 23 months) was safe and well-tolerated, with most adverse events being mild, and suggested potential slowing of cognitive decline, though confirmation requires further controlled studies.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer